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Abstract
Background: Extracellular translationally controlled tumor protein (TCTP) is known to play a role in human allergic
responses. TCTP has been identified outside of macrophages, in activated mononuclear cells, and in biological fluids from
allergic patients. Even TCTP devoid of signal sequences, is secreted to extracellular environment by an yet undefined
mechanism. This study is aimed at understanding the mechanism of TCTP release and its regulation. A secondary goal is to
see if inhibitors of TCTP release can serve as potential anti-allergic asthmatic drugs.
Methodology/Principal Findings: Using Western blotting assay in HEK293 and U937 cells, we found that TCTP secretion is
reduced by omeprazole and pantoprazole, both of which are proton pump inhibitors. We then transfected HEK293 cells
with proton pump expression vectors to search for the effects of exogeneously overexpressed H
+/K
+-ATPase on the TCTP
secretion. Based on these in vitro data we checked the in vivo effects of pantoprazole in a murine model of ovalbumin-
induced allergy. Omeprazole and pantoprazole reduced TCTP secretion from HEK293 and U937 cells in a concentration-
dependent fashion and the secretion of TCTP from HEK293 cells increased when they over-expressed H
+/K
+-ATPase. In a
murine model of ovalbumin-induced allergy, pretreatment with pantoprazole reduced infiltration of inflammatory cells,
increased goblet cells, and increased TCTP secretion induced by OVA challenge.
Conclusion: Since Omeprazole and pantoprazole decrease the secretion of TCTP which is associated with the development
of allergic reaction, they may have the potential to serve as anti-allergic (asthmatic) drugs.
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Introduction
Translationally controlled tumor protein (TCTP) is expressed in
almost all mammalian tissues. Intracellular TCTP levels respond
to various extracellular signals and agents such as growth factors,
cytokines, and stress conditions [1–3]. Extracellular TCTP has
also been reported to be present in the supernatants of human
U937 macrophage cell cultures [4], outside of mononuclear cells
and platelets, in nasal washings, skin blister fluids, and broncho-
alveolar lavage (BAL) fluids during late allergic reactions [5–9].
Human recombinant TCTP stimulates the secretion of histamine,
IL-4 and IL-13 from basophils. TCTP also causes chemotaxis and
IL-8 secretion from eosinophils [10,11].
Most secretory proteins have signal sequences composed of 13–
30 hydrophobic amino acids at their N-termini. Some leaderless
proteins, however, can exit from a cell in an ER-Golgi
independent fashion, for example, interleukins 1a and 1b,
FGF2, thioredoxin, lipocortin, galectin, HIV-tat protein, annexin,
and vas deferens protein. TCTP, with no classical leader sequence
that might explain its extracellular presence, belongs to these
unusual proteins, which exit from a cell without passing through
the classical secretion pathway [12,13]. How these proteins are
non-classically secreted from cell has not yet been defined.
Contrary to an early perception, the selective release of the
‘leaderless’ proteins can be unequivocally distinguished from
conventional ER-Golgi-mediated protein secretion which is not a
consequence of impaired plasma membrane integrity or cell death.
Several potential mechanisms were proposed for such unconven-
tional protein secretion, involving: lysosomal and exosomal
secretion, plasma membrane resident transporters, and membrane
blebbing [14], but a definitive understanding of the secretion
mechanism for leaderless proteins has not emerged.
Omeprazole is an active ingredient of Prilosec, used to treat
peptic ulcer. It is a specific inhibitor of the human gastric H
+/K
+-
ATPase [15], which at neutral pH, permeates cell membranes and
accumulates in acidic cellular compartments, such as lysosomes,
where it undergoes protonation. The protonated form becomes an
active sulfenamide compound and acts as a potent proton pump
inhibitor (PPI) [16]. Activated omeprazole was shown to inhibit
human gastric H
+/K
+-ATPase and halt acid secretion by parietal
cells [17]. Pantoprazole is a modified form of omeprazole and also
is also a PPI. PPIs have also been shown to inhibit neutrophil
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phagocytosis, acidification of phagolysosomes [21], and produc-
tion of reactive oxygen intermediates [22].
Although the secretion of TCTP is well documented, how it is
regulated is not clear. Because the factors contributing to its
secretion and the underlying mechanisms are still unclear we tried
various ATPase inhibitors (Na
+/K
+-ATPase, plasmamembrane
H
+/K
+-ATPase, plasmamembrane Ca
2+-ATPase) based on the
report that FGF-2 release is related to Na
+/K
+-ATPase inhibitors
[23]. We found that omeprazole and pantoprazole inhibit TCTP
release in a concentration-dependent fashion in vitro.W e
confirmed this phenomenon in vivo and came to the conclusion
that omeprazole and pantoprazole have the anti-allergic asthmatic
potential by reducing TCTP secretion.
Methods
Antibodies
Mouse 12CA5 anti-HA monoclonal antibody, purified rabbit
anti-GFP polyclonal antibody, mouse anti-Na
+/K
+-ATPase a1
monoclonal antibody (C464.6), and anti-flagH M2 monoclonal
antibody were purchased from Zymed Laboratories Inc., InVitro-
gen, Upstate, and Sigma, respectively.
Cell culture and cell secretion assays
HEK293 cells (ATCC) were cultured in Dulbecco’s modified
Eagle’s media (DMEM; Invitrogen) containing 10% fetal bovine
serum, 1% penicillin-streptomycin, 2 mM glutamine, and 20 mM
HEPES. U937 cells (ATCC) were cultured in RPMI-1640 media
(Invitrogen) containing 10% fetal bovine serum, 1% penicillin-
streptomycin, and 10 mM HEPES. On the day of experiment,
HEK293 cells were detached from culture dishes, using with
trypsin-EDTA, and washed twice with serum-free media. U937
cells were collected by centrifugation and washed twice with
serum-free media. The collected cells were stained with trypan
blue, counted for live cells, and plated. The cells were resuspended
in serum-free media and incubated for indicated times with or
without omeprazole (Sigma) and pantoprazole (Byk Gulden,
Germany) or ionomycin (Sigma). Cell viability was assessed by
trypan blue exclusion or CCK-8 (Dojindo Molecular Technolo-
gies, Japan). At the end of incubation, supernatants were collected
and centrifuged (3006g) for 5 min to remove non-adherent cells.
The supernatants were recentrifuged (5,0006g) for 10 min to
remove cell debris and nuclei and concentrated by centrifugation
using vivaspin 500 (10,000 molecular weight cut-off; Sartorius,
France), and resuspended in 46SDS sample buffer. Each sample
(indicated amount of total proteins was resolved by SDS-PAGE.
Cells were solubilized in lysis buffer containing 1% Nonidet P-40,
50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.25%
deoxycholate, 2 mM sodium orthovanadate, 1 mM sodium
fluoride and mixture of protease inhibitors. After transfer the
membranes were routinely blotted.
Plasmid construction
To construct the plasmid, human TCTP/p3XFLAG-CMV-14,
human TCTP insert was made by PCR amplification using
primers with BamHI and EcoRI sites. Insert DNA and p3XFLAG-
CMV-14 empty vector were excised by BamHI and EcoRI
restriction enzymes and sticky-end ligated. The plasmid was
confirmed by DNA sequencing. To construct the plasmid, rat H
+/
K
+-ATPase a1/pEGFP-N1, rat H
+/K
+-ATPase a1 insert was
made by PCR amplification using primers with HindIII and XhoI
sites. Insert DNA and pEGFP-N1 empty vector were excised by
HindIII and XhoI restriction enzymes and sticky-end ligated. The
plasmid was confirmed by DNA sequencing. Rat Na
+/K
+-ATPase
b1/pcDNAI-neo was constructed as previously described [24].
Transfections
HEK293 cells were plated and a day later, transfected by the
Ca2PO4 precipitation method or WelFect EX PLUS reagent
(WelGene, Korea). In triple transfections, the ratio of rat H
+/K
+-
ATPase a1-GFP: HA-rat Na
+/K
+-ATPase b1: human TCTP-3X
flag was 3:1:1. Secretion assays were performed after 2 days. In
some experiments, omeprazole or pantoprazole was added during
the secretion assay.
Development of airway inflammation
Male BALB/c mice were purchased from the Central Lab.
Animal Inc. (Korea), and were kept in our animal facility for at
least 1 week before use. All animals were handled in strict
accordance with good animal practice as defined by the relevant
national and/or local animal welfare bodies, and all animal work
was approved by Ewha Womans University’s institutional animal
care and use committee. The mice were sensitized on day 0, and
on day 14, with intraperitoneal (i.p.) injection of OVA (Sigma,
50 mg per each) in alum (Thermo scientific). Starting on day 28,
the sensitized mice were challenged with daily intranasal injections
(with pipetman) of PBS or OVA (300 mg per each) for seven days.
For pantoprazole treatment, the mice were pre-treated (i.p.) with
indicated dose of Pantoloc containing pantoprazole as active
ingredient; (Byk Gulden, Germany) 30 min prior to OVA
challenge and sacrificed on day 37. Bronchoalveolar lavage lung
fluids (BALF) and lungs were collected. Western blotting for
TCTP detection was performed on BALF.
Lung analyses
Lung tissues were fixed in 4% paraformaldehyde, dehydrated in
alcohol, embedded in paraffin and cut into 5 mm thick slices.
Tissue section was stained with PAS solution (Sigma). Images were
acquired using optical microscope (Nikon Eclipse E200, Japan).
Statistics
Data are expressed as mean6S.D. Significances of differences
between two groups were determined using the unpaired student’s
t-test. Statistical significance was set at p,0.05.
Results
Omeprazole and pantoprazole inhibit TCTP secretion
from U937 and HEK293 cells
We first established the incubation period needed for detection
of secreted TCTP. Extracellular TCTP was first identified in the
supernatants of U937 cells [4] and further studies on TCTP
release were done using HEK293 cells. U937 cells were incubated
in serum-free RPMI media for 0, 1, 2, 3, 4, or 5 h, and the
collected supernatants and cells were processed, resolved by SDS-
PAGE, and immunoblotted for TCTP. The secreted amount of
TCTP increased with incubation time and reached maximum
after 5 h incubation (Figure 1A). To ensure that TCTP resulted
from an active secretion process rather than from contamination
from cell lysis or non-specific release, the supernatants were also
immunoblotted against b-tubulin, one of the abundant cytosolic
proteins. Beta tubulin was clearly identified in cell lysates but not
in the corresponding supernatants (Figure 1A). In HEK293 cells, it
was difficult to detect the secretion of endogeneous TCTP.
HEK293 cells were therefore transfected with TCTP-3Xflag and 2
days later placed in serum-free media and their supernatants were
TCTP Secretion
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were incubated in serum-free DMEM media for 0, 0.5, 1, or 3 h,
and the collected supernatants and cells were processed, and
resolved by SDS-PAGE, and immunoblotted for TCTP-3Xflag.
By 1 h, exogenously expressed TCTP was detected in HEK293
cell-derived supernatants; these levels were not further enhanced
at 3 h. As with U937, there was no evidence of cell lysis or non-
specific protein release (Figure 2A).
When the secretion assays were performed with serum-free
media supplemented with omeprazole or pantoprazole, the
amounts of TCTP detected in the conditioned media were
reduced in a concentration dependent fashion. In U937 cells,
Figure 1. TCTP secretion, both constitutive and induced from U-937 cells is inhibited by omeprazole and pantoprazole. (A) TCTP
secretion is increased with incubation time in serum-free conditioned media. b-tubulin is a loading control in cells, while it is a cell lysis marker in
media. WB: anti-b-tubulin Ab (rabbit polyclonal antibody, H-235, Santa Cruz Biotechnology) and anti-TCTP Ab (rabbit polyclonal antiserum, generated
using recombinant His-tagged TCTP as the immunogen), (B) Omeprazole treatment during incubation in conditioned media (5 h) is capable of
decreasing of TCTP secretion in concentration-dependent manner. ‘O’ in the graph means omeprazole. WB: anti-TCTP Ab, (C) Pantoprazole treatment
(5 h) inhibits TCTP secretion in concentration-dependent manner. ‘P’ in the graph means pantoprazole. WB: anti-TCTP Ab, (D) Both of omeprazole (O)
and pantoprazole (P) pre-treatments reduce the TCTP secretion induced by ionomycin (IM) treatment (2 mM, 10 min). 1 mM omeprazole and 100 mM
pantoprazole were used. Both chemicals were treated 1 h prior to ionomycin treatment. WB: anti-TCTP Ab. Data from panel B to panel D represent
means6S.D. from three independent experiments. #: inhibition, p,0.05, vs. non-treated cells (panel B, C), vs. IM-treated cells (panel D), ##:
inhibition, p,0.01, vs. non-treated cells (panel B, C), vs. IM-treated cells (panel D), **: increase, p,0.01, vs. non-treated cells.
doi:10.1371/journal.pone.0005732.g001
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(Figure 1B) and by 50% with 100 mM pantoprazole (Figure 1C).
In HEK293 cells, the reduction of TCTP secretion was 60% and
40% for omeprazole and pantoprazole, respectively (Figure 2B,
2C). In these experiments, we used omeprazole at lower
concentration than pantoprazole for the following reasons. First,
Figure 2. The secretion of exogeneously expressed TCTP in HEK293 cells is inhibited by omeprazole and pantoprazole. (A) TCTP
secretion is increased with incubation time in serum-free conditioned media. b-tubulin is a loading control in cells, while it is a cell lysis marker in
media. WB: anti-b-tubulin Ab and anti-flag Ab, (B) Omeprazole treatment during incubation in conditioned media (3 h) is capable of decreasing of
TCTP secretion in concentration-dependent manner. ‘O’ in the graph means omeprazole. WB: anti-flag Ab, (C) Pantoprazole treatment (3 h) inhibits
TCTP secretion in concentration-dependent manner. ‘P’ in the graph means pantoprazole. WB: anti-flag Ab, (D) Both of omeprazole (O) and
pantoprazole (P) pre-treatments reduce the TCTP secretion induced ionomycin (IM) treatment (2 mM, 10 min). 1 mM omeprazole and 100 mM
pantoprazole were used. Both chemicals were treated 1 h prior to ionomycin treatment. WB: anti-flag Ab. Data from panel B to panel D represent
means6S.D. from three independent experiments. #: inhibition, p,0.05, vs. non-treated cells (panel B, C), vs. IM-treated cells (panel D), ##:
inhibition, p,0.01, vs. non-treated cells (panel B, C), vs. IM-treated cells (panel D), **: increase, p,0.01, vs. non-treated cells.
doi:10.1371/journal.pone.0005732.g002
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100 mM, probably due to the excessive inhibition of H
+/K
+-
ATPase. Second, the reconstituted pantoprazole caused precipi-
tation after freezing and thawing and precipitation causes some
reduction in activity. To avoid such precipitations, it was dissolved
as soon as it was reconstituted, and divided into small aliquots.
The viability of the cells treated by omeprazole and pantoprazole
was confirmed with trypan blue or CCK-8 kit; there was no
significant difference between untreated and treated cells. The
inhibition of TCTP secretion by omeprazole and pantoprazole
was also seen in ionomycin (IM) treated cells. IM is a Ca
2+
ionophore and induces secretion of many proteins in an ER-Golgi
independent process. With U937 cells, IM treatment increased
TCTP secretion by approximately 50% and pre-treatment with
omeprazole and pantoprazole blocked this increase (Figure 1D).
HEK293 cells transfected with TCTP-3Xflag also showed similar
patterns (Figure 2D).
These results indicate that omeprazole and pantoprazole inhibit
TCTP secretion, regardless of whether it is endogeneously or
exogeneously expressed. Also secretion inducers had no effects on
these phenomena.
a-subunit of H
+/K
+-ATPase modulates TCTP export
The major effect of PPIs is to inhibit the ion transport activity of
H
+/K
+-ATPase by binding to the catalytic a-subunit. Since
omeprazole and pantoprazole inhibited TCTP export, we
investigated whether changes in a-subunit level of H
+/K
+-ATPase
affect TCTP export. HEK293 cells were co-transfected with
plasmid expression vectors encoding TCTP, rat a1-subunit of H
+/
K
+-ATPase, and rat b1-subunit of Na
+/K
+-ATPase. As shown in
Figure 3B, co-overexpression of a1 and b1 with TCTP elevated
TCTP secretion by over 60%, compared with control cells
expressing TCTP only. This increase was not seen in the cells
transfected with b1 and TCTP except a1. This suggests that the
complex of a1-subunit and b1-subunit is in some way involved in
TCTP export. TCTP secretion induced by co-expression of a1
and b1 was reduced by pre-treatment of omeprazole and
pantoprazole (Figure 3C). But only pantoprazole had a statistically
significant effect. Since the concentration of omeprazole and
pantoprazole used in Figure 2 was not sufficient to reverse the
increase of TCTP release, a tenfold concentration was used. Cell
viability was not changed by these pre-treatments.
Effect of pantoprazole on the TCTP levels in BAL fluids
from OVA-sensitized mice
It has been shown that TCTP appears in biological fluids during
the late allergic reaction [5–9]. We used the OVA-challenged mice
for examining the effect of pantoprazole in vivo. Periodic Acid-
Schiff (PAS) staining of lung sections showed a marked increase in
mucus-producing granular goblet cells in the proximal airways of
OVA-sensitized/challenged mice relative to saline-treated control
mice (Figure 4A). The increase of PAS positive goblet cells in mice
were reduced by pretreatment with pantoprazole in a dose
dependent manner. Pantoprazole pre-treatment also reduced
markedly, the infiltration of the airway wall by PAS positive
inflammatory cells. Increase of mucus-producing goblet cells and
inflammatory cell infiltration is a prominent histopathological
feature of the murine asthmatic lung.
Figure 3. Increased TCTP secretion by over-expression of proton pump is inhibited by pantoprazole in HEK293. (A) Comparison of
protein expressions in control and Hab samples. Control sample was transfected with two empty vectors (pEGFP-N1 and pcDNAI-neo) and TCTP-
3Xflag construct. Hab sample was transfected with rat H
+/K
+-ATPase a1-GFP, HA-rat Na
+/K
+-ATPase b1, and TCTP-3Xflag constructs. WB: anti-GFP Ab
(purified rabbit polyclonal antibody, InVitrogen), anti-HA Ab (mouse 12CA5 monoclonal antibody, Santa Cruz), and anti-flag Ab, (B) TCTP secretion is
increased by over-expression of H
+/K
+-ATPase a1 and Na
+/K
+-ATPase b1. Both groups of cells were incubated for 3 h in conditioned media. WB: anti-
flag Ab, (C) The secretion assay data for the cells transfected with H
+/K
+-ATPase a1, Na
+/K
+-ATPase b1, and TCTP. Pantoprazole (1 mM) or omeprazole
(1 mM) was treated during 3 h secretion assay. ‘O’ in the graph means omeprazole and ‘P’ does pantoprazole. WB: anti-flag Ab. Data of panel B and
panel C represent means6S.D. from three independent experiments. #: inhibition, p,0.05, vs. non-treated cells, *: increase, p,0.05, vs. the cells
transfected with two empty vectors (pEGFP-N1 and pcDNAI-neo) and TCTP-3Xflag construct.
doi:10.1371/journal.pone.0005732.g003
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fluids. As shown in Figure 4B, OVA challenged mice showed
increased TCTP in BAL fluids. Similar to in vitro data,
pantoprazole pre-treatment inhibited TCTP secretion to that
present in sham group. These results indicate that pantoprazole
might exert its anti-allergic effect by blocking TCTP secretion.
Discussion
TCTP is known to be a secreted protein, but the factors
contributing to its secretion and the underlying mechanisms are
still unclear. There are many studies about the secretion
mechanisms of the other non-typically secreted proteinsother than
TCTP. Secretion of the catalytic subunit of Na
+/K
+-ATPase is
reported to be related to fibroblast growth factor-2 (FGF-2). In this
study, the authors searched for some small molecules that might
cause specific perturbation of the plasma membrane and interfere
with FGF-2 release. They assumed that there is a plasma
membrane translocation apparatus (PMTA) through which
FGF-2 is exported. They found cardenolides like ouabain inhibit
FGF-2 secretion and that Na
+/K
+-ATPase acts as a PMTA
component or regulator. Based on this report, we searched for the
inhibitors that act on plasma membrane and inhibit TCTP
secretion. Eventually we found that proton pump inhibitors (PPIs)
such as omeprazole and pantoprazole decrease the leaderless
TCTP export. Possible cytotoxic effects of omeprazole and
pantoprazole could be ruled out, since the trypan blue or CCK-
8 assay showed no toxic effects when these drugs were used. Also,
reduction in TCTP secretion by PPIs did not result from altered
protein synthesis or increased instability of intracellular pools,
because the treatment with these drugs did not modify the
amounts of the intracellular proteins remarkably (Figs. 1B, 2B).
Omeprazole is used to treat peptic ulcer because it is a specific
inhibitor of the human gastric H
+/K
+-ATPase. It is a proton
pump inhibitor (PPI). Other Chemicals containing pantoprazole,
rabeprazole, lansoprazole, and esomeprazole are also PPIs. PPIs
interact with the catalytic a-subunit of H
+/K
+-ATPase and
thereby inhibit its ability to exchange K
+ for H
+, hydrolyze
ATP, and maintain an electrochemical gradient across the plasma
membrane. In addition to reduction of gastric acid secretion
through H
+/K
+-ATPase inhibition, various biological effects of
omeprazole have been investigated, including antileishmanial
(antimicrobial) activity [25], relaxation of human arteries [26], and
inhibition of neutrophil chemotaxis [27]. Although the major
target of PPIs is heretofore believed to be gastric H
+/K
+-ATPase
(known to be mainly in parietal cells of stomach), other molecules,
for example putative H
+/K
+-ATPase that are sensitive to PPIs and
are unrelated to gastric H
+/K
+-ATPase or completely new targets
other than proton pump, might be influenced by PPIs, considering
the effects of PPIs on neutrophils or arteries. The data presented
here suggest that the new activities of PPIs should be evaluated in
the light of their role as inhibitors of TCTP and in the export of
unidentified proteins export via ER-Golgi independent secretion
pathways.
Several possible models can link, at the molecular level, the
known actions of PPIs, their effect on their target (the a1-subunit
of H
+/K
+-ATPase) and their ability to inhibit TCTP export. For
example, the translocation apparatus exporting TCTP from cells
may be regulated via the electrochemical gradient maintained by
H
+/K
+-ATPase. If this model is correct, one needs to examine the
Figure 4. Pantoprazole alleviates asthmatic responses and inhibits TCTP secretion in OVA-sensitized/challenged mice. (A) PAS
staining results of lung sections. OVA-sensitized/challenged mice show marked increase of the mucus-producing granular goblet cells in the
bronchial alveoli relative to sham mice. The increased PAS positive goblet cells in OVA challenged mice were reduced by pantoprazole pre-treatment
in amount dependent manner. Pantoprazole pre-treatment also reduced marked infiltration of the airway wall by PAS positive inflammatory cells, (B)
Western blotting data using BALF of allergic mouse model. WB: anti-TCTP antibody. Mice were sensitized with OVA and challenged with PBS or OVA
five times every other day. ‘P’ means pantoprazole and indicated numbers (10 and 100) mean dosage. #: inhibition, p,0.05, vs. OVA challenged but
no pre-treatment, ##: inhibition, p,0.01, vs. OVA challenged but no pre-treatment, **: increase, p,0.01, vs. sham group. sham: negative control,
OVA sensitized but not challenged, n=4. OVA: positive control, OVA sensitized and challenged with no pre-treatment, n=5. P 10: OVA sensitized and
challenged with pantoprazole 10 mg/kg pre-treatment (30 min), n=6. P 100: OVA sensitized and challenged with pantoprazole 100 mg/kg pre-
treatment (30 min), n=6.
doi:10.1371/journal.pone.0005732.g004
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+/K
+-ATPase in U937 and HEK293 cells.
Western blotting analysis using the cell lysates of U937 and
HEK293 cells, showed several bands detected by anti-gastric H
+/
K
+-ATPase a antibody (data not shown). But the detected proteins
were smaller than expected. This indicates either that gastric H
+/
K
+-ATPase a does not exist in these cells or that new, modified
forms of gastric H
+/K
+-ATPase a might exist. It is also possible
that there is a novel PPIs-sensitive protein target that is distinct
from the catalytic a-subunit of H
+/K
+-ATPase, even though thus
far, the main binding target of PPIs is the catalytic a-subunit of
H
+/K
+-ATPase. Next possibility is the H
+/K
+-ATPase blockade
may modify ongoing intracellular events, such as calcium influx
and calcium mobilization, and modulate TCTP release. In
previous studies, it was reported that PPIs could affect the
intracellular calcium level [28,29] and tat exocytosis is one of the
mechanisms of TCTP secretion [30]. The changes in intracellular
calcium levels caused by PPIs might influence exocytosis and
subsequently TCTP secretion.
TCTP has been implicated in various cellular processes, such as
cell growth, cell cycle progression, malignant transformation,
protection of cells against stress and apoptosis. In addition, an
extracellular, cytokine-like functions have been established for
TCTP. Thus far, there have been no reports showing that changes
in intracellular TCTP levels influence the severity of allergic
responses or regulation of various allergic cytokines. For TCTP to
act as a regulator of allergic responses, it should be released from
cells. TCTP cannot affect downstream effector cells until it is
secreted. Because of their ability to inhibit TCTP secretion in vitro
and in vivo, omeprazole and pantoprazole might be potentially
useful as anti-allergic asthmatic therapies.
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